Sionna Therapeutics Reports Q3 GAAP EPS Miss of $0.09
Sionna Therapeutics (SION) reported third-quarter GAAP earnings per share of -$0.72, missing analyst expectations by $0.09. Despite the earnings miss, the company maintains a significant liquidity position to support its long-term development goals. As of September 30, 2026, Sionna Therapeutics reported a cash position of $249.8 million. Management expects these existing funds to be sufficient to finance company operations through the second half of 2029.
Tickers: $SION